The Influence of Non-High-Density Lipoprotein Cholesterol on the Efficacy of Genotype-Guided Dual Antiplatelet...

Area of Science:

• Cardiovascular Medicine
• Neurology
• Pharmacology

Background:

• Non-high-density lipoprotein cholesterol (non-HDL-C) is a key target for lipid-lowering therapy in high-risk patients.
• Guidelines now include non-HDL-C as a therapeutic target for atherosclerotic disease.
• Understanding non-HDL-C's role in antiplatelet therapy is crucial for stroke prevention.

Purpose of the Study:

• To investigate the relationship between non-HDL-C levels and the effectiveness of ticagrelor-aspirin versus clopidogrel-aspirin.
• To assess the safety of ticagrelor-aspirin compared to clopidogrel-aspirin in relation to non-HDL-C levels.
• To determine if non-HDL-C influences the efficacy of dual antiplatelet therapy in preventing recurrent stroke.

Main Methods:

• Post hoc analysis of the CHANCE-2 trial involving 5,901 patients.
• Patients were stratified by median non-HDL-C levels (cutoff 3.5 mmol/L).
• Primary outcomes included recurrent stroke and major/moderate bleeding within 90 days.

Main Results:

• Ticagrelor-aspirin significantly reduced recurrent stroke in low non-HDL-C patients (HR 0.54) but not in high non-HDL-C patients (HR 0.88).
• A significant interaction (P=0.010) indicated that ticagrelor-aspirin's benefit decreased with increasing non-HDL-C.
• No significant difference in bleeding rates was observed between treatment groups across non-HDL-C levels.

Conclusions:

• Patients with low non-HDL-C levels experienced greater clinical benefit from ticagrelor-aspirin compared to clopidogrel-aspirin.
• High non-HDL-C levels may attenuate the benefit of ticagrelor-aspirin in preventing stroke recurrence.
• Non-HDL-C level is an important factor in tailoring dual antiplatelet therapy post-stroke.